Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG’s Chief Financial Officer, who files individually, reported automatic sales of company stock. On December 22, 2025, the officer sold a total of 10,000 common shares of CRISPR Therapeutics AG in three separate transactions, at weighted average prices of $55.1022, $56.3345, and $56.8858 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, which is designed to provide an affirmative defense for insiders trading under predetermined instructions. After these sales, the officer beneficially owns 6,767 common shares directly.
CRISPR Therapeutics AG reported a wider quarterly loss as collaboration and R&D spending remained high. For Q3 2025, total revenue was $0.9 million from grants, while operating expenses reached $132.9 million, driven by $58.9 million in research and development and $57.1 million in collaboration expense, net. Net loss was $106.4 million (basic and diluted loss per share $1.17).
Year to date, the company recorded a $451.0 million net loss, including $96.3 million of acquired in‑process R&D tied to the Sirius collaboration. Liquidity remained strong with $286.5 million in cash and cash equivalents and $1,629.2 million in current marketable securities, plus $28.4 million non‑current. Shareholders’ equity stood at $1.916 billion. The company continued equity financing, issuing 5.1 million shares under its 2021 ATM for $286.8 million in net proceeds, and later launched a new 2025 ATM. As of September 30, 2025, 93,872,794 common shares were outstanding.
CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025. The company provided the full details in a press release attached as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, and therefore are not subject to Section 18 liabilities or incorporated by reference except as specifically stated. The 8‑K was signed by CEO Samarth Kulkarni, Ph.D., on November 10, 2025.
CRISPR Therapeutics (CRSP) Form 4: On October 16, 2025, the CEO and director reported the vesting and settlement of 100,000 restricted stock units into common shares. On October 17, 2025, 50,895 common shares were sold at $67.91 to cover tax withholding mandated by company policy. Following these transactions, holdings were 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The RSU grant leaves 300,000 RSUs scheduled to vest annually through October 2028.
CRISPR Therapeutics (CRSP) reported an insider equity event. The company’s General Counsel and Secretary had 2,114 restricted stock units settle into common shares on 10/13/2025. On 10/14/2025, 1,076 shares were sold at $66.6 to cover tax withholding under the company’s RSU Settlement Policy, described as a non-discretionary sale.
Following these transactions, the insider directly owned 83,402 common shares. A remaining balance of 2,113 RSUs is reported outstanding.
CRISPR Therapeutics AG launched an at‑the‑market offering of up to $600,000,000 of common shares, to be sold from time to time through Jefferies as sales agent under an existing Sales Agreement. Sales may be made in transactions deemed an “at the market offering” under Rule 415(a)(4). Jefferies will use commercially reasonable efforts and earn a commission of up to 3.0% of the gross sales price; there is no escrow arrangement.
The company expects to use potential net proceeds to fund research and clinical development, platform extensions, manufacturing infrastructure, working capital and general corporate purposes. Estimated offering expenses are approximately $6.4 million, which include a Swiss federal securities issuance stamp tax of 1%.
The prospectus provides an illustrative dilution scenario assuming sales at $68.29 per share, showing immediate dilution of $44.76 per share to new investors. Common shares outstanding were 88,376,439 as of June 30, 2025.
CRISPR Therapeutics AG filed a prospectus supplement to offer and sell, from time to time and at its sole discretion through Jefferies as sales agent, additional common shares with an aggregate offering price of $600,000,000. The common shares will be issued under the company’s automatically effective shelf registration statement on Form S-3ASR (File No. 333-281262) filed on August 5, 2024.
The filing notes the engagement of Jefferies LLC under an existing Open Market Sale Agreement and includes a legal opinion from Walder Wyss AG as Exhibit 5.1. This action provides the company with the ability to raise capital over time via open market sales, subject to applicable securities laws.
CRISPR Therapeutics (CRSP) insider activity: The company’s Chief Executive Officer and Director reported the vesting of 8,334 restricted stock units on 10/13/2025, increasing direct holdings. On 10/14/2025, 4,242 common shares were sold at $66.6 to satisfy tax withholding mandated by the company’s RSU Settlement Policy.
Following these transactions, directly held common shares were 205,096, with an additional 85,662 held indirectly via The Kulkarni 2023 GRAT. The RSU grant was part of a 25,000‑share award vesting in three annual tranches.
CRISPR Therapeutics (CRSP) reported an insider equity award. The Chief Executive Officer and Director received a stock option covering 49,500 Common Shares on October 3, 2025 with an exercise price of $67.74 per share. The option vests in 48 equal monthly installments, beginning November 3, 2025, and expires on October 3, 2035. The filing lists the holding as Direct ownership.
CRISPR Therapeutics AG (CRSP) reported an insider equity award. The company’s Chief Medical Officer received a stock option covering 16,500 common shares with an exercise price of $67.74 on October 3, 2025. The option expires on October 3, 2035.
The award vests in 48 equal monthly installments, beginning November 3, 2025. Following the grant, 16,500 derivative securities were beneficially owned, shown as Direct (D) ownership.